4.7 Review

Histone deacetylase inhibitors: Mechanisms of cell death and promise in combination cancer therapy

期刊

CANCER LETTERS
卷 269, 期 1, 页码 7-17

出版社

ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2008.03.037

关键词

historic deacetylase inhibitor; apoptosis; autophagy; bortezomib; TRAIL

类别

资金

  1. Institute for Drug Development, Cancer Therapy and Research Center at The Umversity of Texas Health Science Center at San Antonio

向作者/读者索取更多资源

Histone deacetylases (HDACs) play an important role in the epigenetic regulation of gene expression by catalyzing the removal of acetyl groups, stimulating chromatin condensation and promoting transcriptional repression. Since aberrant epigenetic changes are a hallmark of cancer, HDACs are a promising target for pharmacological inhibition. HDAC inhibitors can induce cell-cycle arrest, promote differentiation, and stimulate tumor cell death. These properties have prompted numerous preclinical and clinical investigations evaluating the potential efficacy of HDAC inhibitors for a variety of malignancies. The preferential toxicity of HDAC inhibitors in transformed cells and their ability to synergistically enhance the anticancer activity of many chemotherapeutic agents has further generated interest in this novel class of drugs. Here we summarize the different mechanisms of HDAC inhibitor-induced apoptosis and discuss their use in combination with other anticancer agents. (C) 2008 Elsevier Ireland Ltd. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据